Pathway Genomics vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
CAP- and CLIA-accredited clinical genetic testing lab offering cancer risk, cardiac, pharmacogenomics, and wellness panels to physicians and patients; privately held, San Diego, founded 2008.
About
Pathway Genomics (also known as Pathway OME) is a privately held clinical genetic testing company founded in 2008 and headquartered in San Diego, California. The company operates a CAP-accredited and CLIA-certified clinical laboratory that provides physicians and patients with actionable, precision healthcare information derived from genetic analysis. Pathway's testing services cover cancer risk assessment, cardiac health, pharmacogenomics (drug response), inherited disease risk, nutrition and exercise response, and reproductive health — enabling personalized healthcare decisions grounded in genetic data.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.